PDL BioPharma Completes Spin-Off of LENSAR
PDL stockholders received 0.075879 shares of LENSAR common stock for every one share of PDL common stock outstanding at
Read more about LENSAR at the company's website, www.lensar.com.
Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies.
For more information please visit https://www.pdl.com/
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including as it relates to the Company's proposed plan of liquidation and the regular-way trading of LENSAR. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's assets and business, including the implementation or success of the Company's monetization strategy/plan of complete liquidation, are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q, filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-completes-spin-off-of-lensar-301144697.html
Jody Cain, LHA Investor Relations, 310-691-7100, email@example.com